Printer Friendly

SCHERING-PLOUGH AND U.S. BIOSCIENCE

 MADISON, N.J., and WEST CONSHOHOCKEN, Pa., May 11 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP) and U.S. Bioscience, Inc. (AMEX: UBS) today announced an agreement giving Schering-Plough exclusive marketing rights in Western Europe to Ethyol, a U.S. Bioscience chemo-radiotherapy protective agent.
 Under the terms of the agreement, Schering-Plough, through an affiliated company, will have exclusive rights to market Ethyol in the countries comprising the European Community and the European Free Trade Association for five years following the approval of Ethyol. The two companies will use their combined sales forces to market Ethyol in years six and seven, with U.S. Bioscience assuming sole marketing rights after year seven.
 Schering-Plough will pay U.S. Bioscience upfront and milestone payments totaling up to $10 million as regulatory and pricing approvals are obtained. In addition to these payments, U.S. Bioscience will receive a share of operating profits from sales of the product in the territories. After assuming sole marketing rights, U.S. Bioscience will pay Schering-Plough a portion of its operating profits in Europe for three years.
 U.S. Bioscience will supply Ethyol to Schering-Plough throughout the period and will be responsible for obtaining regulatory approvals and conducting all clinical trials for the initial and any subsequent extension of indications.
 "This agreement with U.S. Bioscience should further strengthen Schering-Plough's position in Europe," said Rodolfo C. Bryce, president of Schering-Plough International. "When marketed, Ethyol will broaden the company's oncology portfolio, which includes `Eulexin,' a treatment for advanced prostate cancer; `Leucomax,' a GM-CSF for the treatment of neutropenia in chemotherapy; and `Intron A' alpha interferon, for treating various cancers and viral diseases."
 Russell C. McLauchlan, president and chief operating officer of U.S. Bioscience, said: "Schering-Plough is a highly respected and leading marketer of oncology products in Europe and has proven to be a capable and cooperative partner in Latin America and several countries in the Far East. We are delighted to join them in this new venture. This arrangement will allow U.S. Bioscience to concentrate its initial marketing efforts in the United States but at the same time give us the time necessary to fully establish our own commercial presence in Europe."
 Ethyol (amifostine) provides protection against hematological toxicities associated with radiation and chemotherapy and is administered prior to treatment. A health registration application for the product was filed by U.S. Bioscience in 1992 with the European Community's Committee for Proprietary Medicinal Products (CPMP) and the French Ministry of Health, which serves as the rapporteur country for the CPMP application. The CPMP application seeks approval for protection against hematological toxicities associated with certain chemotherapy agents. The agency has classified Ethyol as a "high-tech" product which carries a priority review of the application within the European Community (EC). U.S. Bioscience has received the European Community's consolidated questions on its Ethyol submission and recently met with the rapporteur as part of the Ethyol regulatory approval process which began in September 1992. Responses will be submitted in the coming months.
 Through a 1992 agreement with U.S. Bioscience, Schering-Plough also holds marketing rights to Ethyol, as well as four other anti-cancer products, in a number of countries in Latin America and the Far East. In the United States, U.S. Bioscience has filed a New Drug Application with the Food and Drug Administration seeking approval to market Ethyol as a chemotherapy agent.
 U.S. Bioscience, based in West Conshohocken, is a pharmaceutical company specializing in the development and commercialization of products to increase the survival and quality of life for patients with cancer and allied diseases.
 Schering-Plough, based in Madison, is a research-based pharmaceutical company engaged in the discovery, development, manufacturing and marketing of pharmaceutical and health care products worldwide.
 -0- 5/11/93
 /CONTACT: Robert I. Kriebel of U.S. Bioscience, 215-832-4503, or Ronald J. Asinari of Schering-Plough Corporation, 201-822-7402/
 (SGP UBS)


CO: Schering-Plough Corporation; U.S. Bioscience ST: New Jersey, Pennsylvania IN: MTC SU: JVN

KD-IH -- DC005 -- 6842 05/11/93 08:07 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 11, 1993
Words:665
Previous Article:COKE CONSOLIDATED BOARD DECLARES SECOND QUARTER DIVIDEND
Next Article:WATSCO TO ACQUIRE CENTRAL CALIFORNIA DISTRIBUTOR; FURTHER EXPANDS POSITION AS LARGEST DISTRIBUTOR OF RESIDENTIAL CENTRAL AIR CONDITIONERS
Topics:


Related Articles
U.S. BIOSCIENCE GRANTS SCHERING-PLOUGH MARKETING RIGHTS TO PRODUCTS IN LATIN AMERICA AND FAR EAST
U.S. BIOSCIENCE GRANTS SCHERING-PLOUGH MARKETING RIGHTS TO PRODUCTS IN LATIN AMERICA AND FAR EAST
SCHERING-PLOUGH SIGNS WORLDWIDE AGREEMENT TO DEVELOP AND MARKET CANCER DRUG
U.S. BIOSCIENCE APPOINTS DEPTULA TO MARKETING POST
SCICLONE PHARMACEUTICALS ANNOUNCES CLINICAL DEVELOPMENT/COMMERCIALIZATION AGREEMENT WITH SCHERING-PLOUGH K.K.
SCHERING-PLOUGH UNIT REACHES SETTLEMENT WITH GENENTECH ON PATENT CLAIMS
ALZA AND U.S. BIOSCIENCE ANNOUNCE MARKETING AND DISTRIBUTION AGREEMENT FOR ETHYOL(R) IN THE UNITED STATES
Coley Pharmaceutical Group Expands Management Team.
COLEY PHARMACEUTICAL GROUP EXPANDS MANAGEMENT TEAM.
HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates From China.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters